According to GlobalData’s company profile on Avacta Group, Laboratory automation robots was a key innovation area identified from patents. Avacta Group's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Extended circulating serum half-life therapeutic conjugates

The patent application (Publication Number: US20230390409A1) describes a therapeutic conjugate designed to improve the efficacy of therapeutic moieties by extending their circulating serum half-life in vivo. The conjugate consists of a therapeutic moiety linked through a fibroblast activation protein, alpha (FAPa)-cleavable linker to a half-life extension moiety. Importantly, the conjugate does not contain a cell-binding moiety with a high affinity for cell surface proteins. The half-life extension moiety can include serum proteins like fibronectin, transferrin, or human serum albumin, or molecules that bind to serum proteins, such as antibodies or non-antibody molecules like affibodies or affimers.

Furthermore, the patent application details various formulations and configurations of the therapeutic conjugate, including specific amino acid sequences for the FAPa-cleavable linker, self-immolative linkers, and substrate recognition sequences. The therapeutic moiety can be a cytotoxic, cytostatic, or epigenetic agent, including chemotherapeutic drugs like taxanes or platinum-based agents. The application also covers methods of administering the therapeutic conjugate for treating diseased tissues, particularly cancers, with the aim of increasing efficacy and reducing cytotoxicity. Overall, the patent application outlines a novel approach to enhancing the therapeutic potential of conjugates through targeted delivery and extended half-life in circulation.

To know more about GlobalData’s detailed insights on Avacta Group, buy the report here.